We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Prime time for immunotherapy in advanced urothelial cancer.
Asia-Pacific Journal of Clinical Oncology 2018 November
BACKGROUND: Metastatic urothelial cancer (UC) is a lethal disease. Until 2016, cytotoxic chemotherapy with substantial toxicity was the only therapeutic option. In the first-line metastatic setting, cisplatin-based combination chemotherapy remains the standard of care. For cisplatin-ineligible patients, carboplatin-based regimens that are less efficacious are often substituted. In platinum-refractory patients, taxanes and vinflunine are the most commonly used. Recently, treatment options have largely expanded with the development of the immune checkpoint inhibitors (ICIs). Here, we review the rationale, clinical trial data and recent advances in biomarker development in the field of immuno-oncology in this disease site. We will also explore future directions of the field with respect to sequencing and combination strategies.
METHODS: A comprehensive literature review was performed using Pubmed, clinicaltrials.gov, and conference proceedings from the European Society of Medical Oncology (ESMO) and the American Society of Oncology (ASCO).
RESULTS AND CONCLUSION: ICIs have disease activity in metastatic UC. Five ICIs gained FDA regulatory approval in metastatic UC in patients with platinum-refractory disease. Of these five agents, pembrolizumab has level I evidence based on the KEYNOTE-045 phase III trial showing an overall survival benefit of 3 months over standard chemotherapy. ICIs also play a role in the first-line setting for patients who are cisplatin ineligible. Currently, ICIs are administered to unselected patients as reliable predictive biomarkers are lacking; however, this is a very active area of research. The rapid expansion of ICIs has also led to many upcoming trials, testing ICIs earlier in the disease course and in various combination strategies. Studies on optimal sequencing of therapies are eagerly awaited.
METHODS: A comprehensive literature review was performed using Pubmed, clinicaltrials.gov, and conference proceedings from the European Society of Medical Oncology (ESMO) and the American Society of Oncology (ASCO).
RESULTS AND CONCLUSION: ICIs have disease activity in metastatic UC. Five ICIs gained FDA regulatory approval in metastatic UC in patients with platinum-refractory disease. Of these five agents, pembrolizumab has level I evidence based on the KEYNOTE-045 phase III trial showing an overall survival benefit of 3 months over standard chemotherapy. ICIs also play a role in the first-line setting for patients who are cisplatin ineligible. Currently, ICIs are administered to unselected patients as reliable predictive biomarkers are lacking; however, this is a very active area of research. The rapid expansion of ICIs has also led to many upcoming trials, testing ICIs earlier in the disease course and in various combination strategies. Studies on optimal sequencing of therapies are eagerly awaited.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app